Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.

Aubets J, Jansat JM, Salva M, Birks VM, Cole RJ, Lewis J, Pitcher A, Hall M.

Pharmacol Res Perspect. 2019 Dec 2;7(6):e00540. doi: 10.1002/prp2.540. eCollection 2019 Dec.

PMID:
31832203
2.

Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.

de la Motte S, Beier J, Schmid K, Pascual S, Jansat JM, Gil EG.

Int J Clin Pharmacol Ther. 2012 Jun;50(6):403-12. doi: 10.5414/CP201628.

PMID:
22541745
3.

Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.

Lasseter K, Dilzer S, Jansat JM, Garcia Gil E, Caracta CF, Ortiz S.

Pulm Pharmacol Ther. 2012 Apr;25(2):193-9. doi: 10.1016/j.pupt.2012.02.002. Epub 2012 Feb 15.

PMID:
22366196
4.

Mass balance and metabolism of aclidinium bromide following intravenous administration of [¹⁴C]-aclidinium bromide in healthy subjects.

Ortiz S, Flach S, Ho J, Li F, Caracta CF, Gil EG, Jansat JM.

Biopharm Drug Dispos. 2012 Jan;33(1):39-45. doi: 10.1002/bdd.1773. Epub 2012 Feb 27.

PMID:
22275272
5.

Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.

Ortiz S, Flach S, Caracta C, Gil EG, Jansat JM.

J Clin Pharmacol. 2012 Jun;52(6):819-27. doi: 10.1177/0091270011406281. Epub 2011 May 31.

PMID:
21628603
6.

Pharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trial.

Schmid K, Pascual S, Gil EG, Ortiz S, Jansat JM.

Clin Ther. 2010 Sep;32(10):1798-812. doi: 10.1016/j.clinthera.2010.09.002.

PMID:
21194604
7.

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study.

Schelfhout VJ, Ferrer P, Jansat JM, Peris F, Gil EG, Pauwels RA, Joos GF.

Br J Clin Pharmacol. 2010 May;69(5):458-64. doi: 10.1111/j.1365-2125.2010.03622.x.

8.

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.

Joos GF, Schelfhout VJ, Pauwels RA, Kanniess F, Magnussen H, Lamarca R, Jansat JM, Garcia Gil E.

Respir Med. 2010 Jun;104(6):865-72. doi: 10.1016/j.rmed.2009.12.003. Epub 2009 Dec 30.

9.

Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum.

Timmerman P, Luedtke S, van Amsterdam P, Brudny-Kloeppel M, Lausecker B, Fischmann S, Globig S, Sennbro CJ, Jansat JM, Mulder H, Thomas E, Knutsson M, Kasel D, White SA, Kall MA, Mokrzycki-Issartel N, Freisleben A, Romero F, Andersen MP, Knebel N, de Zwart M, Laakso S, Hucker RS, Schmidt D, Gordon B, Abbott R, Boulanger P.

Bioanalysis. 2009 Sep;1(6):1049-56. doi: 10.4155/bio.09.108.

10.

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects.

Jansat JM, Lamarca R, Garcia Gil E, Ferrer P.

Int J Clin Pharmacol Ther. 2009 Jul;47(7):460-8.

PMID:
19640353
11.

Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.

Jansat JM, Lamarca R, de Miquel G, Schrödter A, Miletzki B, Gurniak M.

J Clin Pharmacol. 2009 Oct;49(10):1239-46. doi: 10.1177/0091270009336353. Epub 2009 Jul 10.

PMID:
19592595
12.

Disposition and metabolism of almotriptan in rats, dogs and monkeys.

Aubets J, Cardenas A, Salva M, Jansat JM, Martinez-Tobed A, Palacios JM.

Xenobiotica. 2006 Sep;36(9):807-23.

PMID:
16971345
13.

Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial.

Jansat JM, Martinez-Tobed A, Garcia E, Cabarrocas X, Costa J.

Int J Clin Pharmacol Ther. 2006 Apr;44(4):185-90.

PMID:
16625988
14.

Pharmacokinetics and safety of oral almotriptan in healthy male volunteers.

McEwen J, Salva M, Jansat JM, Cabarrocas X.

Biopharm Drug Dispos. 2004 Oct;25(7):303-11.

PMID:
15386481
15.

Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan.

Salva M, Jansat JM, Martinez-Tobed A, Palacios JM.

Drug Metab Dispos. 2003 Apr;31(4):404-11.

PMID:
12642466
16.

Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.

Jansat JM, Costa J, Salvà P, Fernandez FJ, Martinez-Tobed A.

J Clin Pharmacol. 2002 Dec;42(12):1303-10.

PMID:
12463724
17.

Almotriptan, a new anti-migraine agent: a review.

Gras J, Llenas J, Jansat JM, Jáuregui J, Cabarrocas X, Palacios JM.

CNS Drug Rev. 2002 Fall;8(3):217-34. Review.

18.

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.

Fleishaker JC, Ryan KK, Jansat JM, Carel BJ, Bell DJ, Burke MT, Azie NE.

Br J Clin Pharmacol. 2001 May;51(5):437-41.

20.

Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods.

Mariño EL, Jansat JM, March MA, Lastra CF.

Int J Clin Pharmacol Ther. 1996 Dec;34(12):546-9.

PMID:
8996850
21.

Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs.

Puigdemont A, Queralt M, Jansat JM, Martinez-Tobed A.

J Pharm Pharmacol. 1994 Jul;46(7):596-9.

PMID:
7996390

Supplemental Content

Loading ...
Support Center